{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.0","upperLimit":"5.0","value":"3.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"120"}],"units":"Participants"}],"description":"Progressive disease was defined as definite enlargement of any existing lesion or any new lesion based on modified Macdonald's criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Temozolomide\n\ntemozolomide: Chemotherapy","id":"OG000","title":"Temozolomide"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"time from registration until date of the first documented progression, an average of 1 year","title":"Time to Tumor Progression","type":"SECONDARY","unitOfMeasure":"years"}